Ascendiant Capital Markets Raises PAVmed (NASDAQ:PAVM) Price Target to $20.00

PAVmed (NASDAQ:PAVM) had its target price lifted by stock analysts at Ascendiant Capital Markets from $19.00 to $20.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of PAVmed in a research report on Saturday, September 27th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $20.00.

PAVmed Stock Up 8.0%

Shares of PAVmed stock opened at $0.49 on Monday. The stock has a market capitalization of $10.65 million, a P/E ratio of 0.42 and a beta of 1.07. The stock has a 50 day moving average price of $0.45 and a two-hundred day moving average price of $0.59. PAVmed has a 12-month low of $0.30 and a 12-month high of $1.29.

Institutional Investors Weigh In On PAVmed

A hedge fund recently raised its stake in PAVmed stock. Jane Street Group LLC grew its holdings in PAVmed Inc. (NASDAQ:PAVM) by 392.9% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 52,676 shares of the company’s stock after buying an additional 41,990 shares during the quarter. Jane Street Group LLC owned 0.31% of PAVmed worth $32,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 19.93% of the company’s stock.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.